The growth in the market will be led by the increase in incidences of infections caused in clinical settings, especially in developing economies owing to their poor hygiene facilities.In terms of product, the HAI diagnostics market is segmented into reagents & consumables and instruments. The reagents & consumables occupied the larger share in the market in 2016 and are expected to maintain the same trend throughout the forecast period. This is attributable to specificity of the reagents providing the accurate results with the target substance in the sample. In medical laboratories, reagents play an important role in diagnostic testing assays of infectious diseases.

Access Detailed Report Summary: https://www.psmarketresearch.com/market-analysis/hospital-acquired-infection-diagnostics-market

In terms of application, the HAI diagnostics market is segmented into drug-resistance testing and disease testing. The drug-resistance testing held the larger share in the market in 2016, owing to the modernization in molecular diagnostics that has enabled drug-resistance testing. With the development of novel testing techniques such as phenotypic resistance testing, hybridization methods, sample processing and sequencing the diagnosis rate has increased to may folds and is expected to grow in near future.

Request to Get the Sample Pages at: https://www.psmarketresearch.com/market-analysis/hospital-acquired-infection-diagnostics-market/report-sample

Technologically advanced products aid by offering accurate and reliable results with low turnaround time. Major companies in the HAI diagnostics market are investing in the development of the molecular diagnostics, looking forward to the growth and demand in the field. For instance, Roche diagnostics, in 2017, launched cobas Liat PCR system with four assays, which also include 20-minute real-time PCR nucleic acid test to detect Clostridium difficile. The company also launched cobas HPV for using on cobas 6800/8800 system for cervical cancer screening, 2017. Cobas 6800/8800 system is a two integrated and fully automated molecular testing system for blood and plasma donor screening. Qiagen N.V., in 2017, launched ipsogen JAK2 RGQ PCR Kit for detection of blood cancer, ipsogen portfolios common, and rare leukemia types.

Make Enquiry Before Buying the Report: https://www.psmarketresearch.com/send-enquiry?enquiry-url=hospital-acquired-infection-diagnostics-market

Some of the key players operating in the HAI diagnostics market are Abbott Laboratories, AstraZeneca plc, Bayer AG, Daiichi Sankyo Co. Ltd., Danaher Corporation, Hologic Inc., Johnson & Johnson, OpGen Inc., and F. Hoffmann-La Roche AG.